A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Reason given: The study is withdrawn due to strategic reasons.
Key facts
- Where
- Conyers, Cumberland, Gurnee, Houston, Lampasas, Little Rock, Longwood, Maumee, Miami, Nashville, Oak Lawn, Ocoee, Pembroke Pines, San Antonio, San Diego, Sherman, Spring Valley, Walnut Creek, and Wilmington, United StatesSee the 21 sites
- Phase
- Phase 2
Where in United States
- Hope Clin Res & WellnessConyers, United StatesNo longer taking part
- Clinical Res CollaborativeCumberland, United StatesNo longer taking part
- Elevate Clinical ResearchGurnee, United StatesNo longer taking part
- The Endocrine CenterHouston, United StatesNo longer taking part
- Radiance Clinical ResearchLampasas, United StatesNo longer taking part
- Arkansas Clinical ResearchLittle Rock, United StatesNo longer taking part
- Future Medical ResearchLongwood, United StatesNo longer taking part
- Advanced Medical Research - MaumeeMaumee, United StatesNo longer taking part
- Clinical Site Partners Kendall Flourish ResearchMiami, United StatesNo longer taking part
- New Horizon Research CenterMiami, United StatesNo longer taking part
- Clinical Research AssociatesNashville, United StatesNo longer taking part
- Accellacare of Duly Oak LawnOak Lawn, United StatesNo longer taking part
- West Orange EndocrinologyOcoee, United StatesNo longer taking part
- American Research Centers of FloridaPembroke Pines, United StatesNo longer taking part
- Center for Diab,Obes & MetabPembroke Pines, United StatesNo longer taking part
- Quality Research IncSan Antonio, United StatesNo longer taking part
- Paradigm Clinical ResearchSan Diego, United StatesNo longer taking part
- Medrasa Clinical ResearchSherman, United StatesNo longer taking part
- Encompass Clinical Research_Spring ValleySpring Valley, United StatesNo longer taking part
- Diablo Clinical Research, Inc.Walnut Creek, United StatesNo longer taking part
- KDCILM, LLC & Accellacare US, Inc.Wilmington, United StatesNo longer taking part
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07357740
- Record updated
- 9 July 2026
- Original description
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.Read full original descriptionShow less
A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18-64 years (both inclusive) at the time of signing the informed consent; Diagnosed with type 2 diabetes mellitus greater than or equal to (>=) 180 days before screening; Glycated haemoglobin (HbA1c) 7.0-10.5 percent (%) (53-91 [millimoles per mole] mmol/mol) (both inclusive) as determined by the central laboratory at screening; Stable daily dose >= 90 days before screening of metformin at effective or maximum tolerated dose as judged by the investigator; Body mass index (BMI) between 25.0 and 39.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
Exclusion: Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening; Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation; Previous exposure to CagriSema in a clinical study; Renal impairment with estimated Glomerular Filtration Rate (eGFR) < 30 millilitre per minute per 1.73 square metre (mL/min/1.73 m\^2) as determined by the central laboratory at screening.